Last reviewed · How we verify
Spironolacton — Competitive Intelligence Brief
marketed
Cytochrome P450 2C19, Multidrug and toxin extrusion protein 1, Nuclear receptor subfamily 1 group I member 2
Cardiovascular
Small molecule
Live · refreshed every 30 min
Target snapshot
Spironolacton (Spironolacton) — ACS Biomarker.
Comparator set (1 drugs)
| Drug | Generic | Sponsor | Phase | Class | Target | Approval / PDUFA |
|---|---|---|---|---|---|---|
| Spironolacton TARGET | Spironolacton | ACS Biomarker | marketed | Cytochrome P450 2C19, Multidrug and toxin extrusion protein 1, Nuclear receptor subfamily 1 group I member 2 | ||
| Aldactone | spironolactone | Generic (originally Searle/Pfizer) | marketed | Aldosterone Antagonist [EPC] | Cytochrome P450 2C19, Multidrug and toxin extrusion protein 1, Nuclear receptor subfamily 1 group I member 2 | 1960-01-01 |
Recent regulatory actions (last 90 days)
Upcoming PDUFA dates (next 180 days)
Patent timeline (forward window)
- — Aldactone · 9757394 · Formulation · US
- — Aldactone · 11395828 · Method of Use · US
- — Aldactone · 10888570 · Formulation · US
- — Aldactone · 11389461 · Formulation · US
- — Aldactone · 10660907 · Formulation · US
- — Aldactone · 10624906 · Formulation · US
- — Aldactone · 10493083 · Formulation · US
- — Aldactone · 11491166 · Formulation · US
Sponsor landscape
Subscribe to ongoing alerts
Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:
- Spironolacton CI watch — RSS
- Spironolacton CI watch — Atom
- Spironolacton CI watch — JSON
- Spironolacton alone — RSS
Cite this brief
Drug Landscape (2026). Spironolacton — Competitive Intelligence Brief. https://druglandscape.com/ci/spironolacton. Accessed 2026-05-13.
Build your own brief
Pick any drug + add comparators:
https://druglandscape.com/ci/{slug}— auto-detected competitorshttps://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3— explicit comparators- Brand names auto-resolve:
/ci/keytruda→ 301 →/ci/pembrolizumab